Global Strategic Investment Solutions LLC Invests $664,000 in Orthofix Medical Inc. $OFIX

Global Strategic Investment Solutions LLC purchased a new stake in shares of Orthofix Medical Inc. (NASDAQ:OFIX) in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 57,875 shares of the medical device company’s stock, valued at approximately $664,000.

Several other large investors have also recently modified their holdings of OFIX. Juniper Investment Company LLC grew its position in Orthofix Medical by 15.3% during the 3rd quarter. Juniper Investment Company LLC now owns 2,847,055 shares of the medical device company’s stock valued at $41,681,000 after purchasing an additional 377,729 shares during the last quarter. Tudor Investment Corp ET AL raised its holdings in Orthofix Medical by 268.8% in the third quarter. Tudor Investment Corp ET AL now owns 217,044 shares of the medical device company’s stock worth $3,178,000 after buying an additional 158,197 shares during the last quarter. JPMorgan Chase & Co. lifted its stake in shares of Orthofix Medical by 33.3% in the third quarter. JPMorgan Chase & Co. now owns 258,035 shares of the medical device company’s stock worth $3,778,000 after buying an additional 64,486 shares in the last quarter. Armistice Capital LLC grew its holdings in shares of Orthofix Medical by 18.4% during the fourth quarter. Armistice Capital LLC now owns 2,648,000 shares of the medical device company’s stock valued at $40,144,000 after buying an additional 412,000 shares during the last quarter. Finally, Inspire Investing LLC grew its holdings in shares of Orthofix Medical by 46.4% during the first quarter. Inspire Investing LLC now owns 45,009 shares of the medical device company’s stock valued at $516,000 after buying an additional 14,255 shares during the last quarter. Hedge funds and other institutional investors own 89.76% of the company’s stock.

Orthofix Medical Trading Up 19.7%

Shares of NASDAQ:OFIX opened at $11.90 on Tuesday. The company has a market cap of $480.96 million, a PE ratio of -7.87 and a beta of 0.71. Orthofix Medical Inc. has a 12-month low of $8.85 and a 12-month high of $16.99. The stock has a 50 day moving average of $10.49 and a 200 day moving average of $12.32. The company has a current ratio of 2.87, a quick ratio of 1.76 and a debt-to-equity ratio of 0.54.

Orthofix Medical (NASDAQ:OFIX) last announced its quarterly earnings data on Tuesday, May 5th. The medical device company reported ($0.52) EPS for the quarter, beating the consensus estimate of ($0.68) by $0.16. The firm had revenue of $196.71 million for the quarter, compared to the consensus estimate of $196.40 million. Orthofix Medical had a negative net margin of 7.27% and a negative return on equity of 13.44%. As a group, equities research analysts expect that Orthofix Medical Inc. will post -1.48 EPS for the current year.

Analyst Ratings Changes

OFIX has been the subject of a number of recent analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of Orthofix Medical in a report on Tuesday, April 21st. TD Cowen reiterated a “hold” rating on shares of Orthofix Medical in a research note on Thursday, May 21st. Stifel Nicolaus lowered their price objective on shares of Orthofix Medical from $18.00 to $15.00 and set a “buy” rating on the stock in a research report on Friday, May 22nd. Wall Street Zen lowered shares of Orthofix Medical from a “buy” rating to a “hold” rating in a research note on Saturday, May 2nd. Finally, Barrington Research upped their price objective on Orthofix Medical from $15.00 to $17.00 and gave the company an “outperform” rating in a research report on Monday. Three investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Orthofix Medical currently has an average rating of “Hold” and an average price target of $16.00.

Insiders Place Their Bets

In other Orthofix Medical news, insider Jorge Andres Cedron sold 3,743 shares of the company’s stock in a transaction that occurred on Thursday, April 16th. The stock was sold at an average price of $12.82, for a total value of $47,985.26. Following the completion of the transaction, the insider directly owned 59,006 shares in the company, valued at $756,456.92. This represents a 5.97% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director John B. Henneman III bought 5,000 shares of the stock in a transaction dated Thursday, May 7th. The stock was bought at an average cost of $12.26 per share, for a total transaction of $61,300.00. Following the acquisition, the director directly owned 90,809 shares of the company’s stock, valued at approximately $1,113,318.34. This represents a 5.83% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders purchased a total of 189,896 shares of company stock valued at $2,293,970 in the last 90 days. 2.70% of the stock is currently owned by company insiders.

Orthofix Medical Company Profile

Orthofix Medical Inc (NASDAQ: OFIX) is a global medical device company focused on the design and development of innovative orthopedic and spinal solutions. The company’s core business is divided into two segments: spine and orthopedics. In the spine segment, Orthofix offers a range of titanium implants, biologics and portable bone growth stimulation devices designed to support spinal fusion, deformity correction and minimally invasive procedures. Its orthopedic segment encompasses products for fracture fixation, external fixation systems, trauma care and sports medicine, providing surgeons with implantable devices and instruments for complex bone reconstruction and healing.

Orthofix’s product portfolio includes strut systems, bone growth stimulators, interbody fusion devices and fixation hardware that address various indications such as degenerative disc disease, spinal deformities, non-unions and long-bone fractures.